Anticryptosporidial Therapeutics The company's lead product group comprises anticryptosporidial proteins which are effective when administered orally in several lab animal models and in calves. Efficacy has been shown against Cryptosporidium parvum and C. hominis. Work is ongoing to develop these both as veterinary and human pharma products.